Bolt Biotherapeutics, Inc. Stock Analysis & AI Score
Bolt Biotherapeutics, Inc. (BOLT) has an ST Score of 23.7 (D+), driven by its Forecast (C+) and held back by its Financial Strength (D-). Analysts rate it Hold with a $4.00 price target (+11.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Bolt Biotherapeutics, Inc. (BOLT) has an ST Score of 23.7 (D+), driven by its Forecast (C+) and held back by its Financial Strength (D-). Analysts rate it Hold with a $4.00 price target (+11.4% upside).
- Strongest
- ForecastC+
- Weakest
- Financial StrengthD-
All factor grades
- ForecastC+
- GrowthC-
- ValuationD+
- MomentumD+
- ProfitabilityD-
- Financial StrengthD-
- Piotroski2/9
Contact
BOLT stock: frequently asked questions
What is BOLT's ST Score?
Bolt Biotherapeutics, Inc. (BOLT) has an ST Score of 23.7 (D+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BOLT a buy, hold, or sell?
Analysts rate BOLT a Hold, with a price target of $4.00 (+11.4% vs the current price). Our ST Score grades it D+ (23.7/100). The ST Score is a data-driven signal, not a recommendation.
What are BOLT's factor grades?
Valuation D+, Profitability D-, Financial Strength D-, Momentum D+, Growth C-, Forecast C+.
What is BOLT's valuation grade?
Bolt Biotherapeutics, Inc. (BOLT) earns a valuation grade of D+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BOLT's growth grade?
Bolt Biotherapeutics, Inc. (BOLT) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BOLT's profitability grade?
Bolt Biotherapeutics, Inc. (BOLT) earns a profitability grade of D-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BOLT's financial strength grade?
Bolt Biotherapeutics, Inc. (BOLT) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BOLT?
The average analyst price target for Bolt Biotherapeutics, Inc. (BOLT) is $4.00 from 8 analysts, which is +11.4% versus the recent price of $3.59.
What is BOLT's Piotroski score?
Bolt Biotherapeutics, Inc. (BOLT) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.